U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283822) titled 'Amping up With PemJAK' on Dec. 06.
Brief Summary: The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Study Start Date: Dec. 03
Study Type: INTERVENTIONAL
Condition:
Non-Hodgkin Lymphoma
Hodgkin Disease Lymphoma
Non-Hodgkin Lymphoma Refractory/ Relapsed
Hodgkin Disease Recurrent
Gray Zone Lymphoma
Peripheral T-cell Lymphoma
Cutaneous T-Cell Lymphomas
Primary Mediastinal B Cell Lymphoma
Intervention:
DRUG: Ruxolitinib
Patients will receive the study drug ruxolitinib for as long as the ...